Human leukocyte antigen class II-melanoma peptide complex (HLA-II-melanoma peptide complex)

Human leukocyte antigen (HLA) class II molecules presenting melanoma peptides are specialized protein complexes essential for the immune system's recognition of malignant melanoma cells. These complexes consist of HLA class II heterodimers (such as HLA-DR, HLA-DP, or HLA-DQ) bound to short peptide fragments derived from melanoma-associated antigens like MAGE-A3, NY-ESO-1, or tyrosinase (Source: Boon et al., 2006, PMID: 16446357). While HLA class II is primarily expressed on professional antigen-presenting cells, its aberrant expression on melanoma cells allows for direct interaction with CD4+ T-helper cells, which can orchestrate a comprehensive anti-tumor response (Source: Pollack et al., 2017, PMID: 28630100). This interaction is a key target for modern immunotherapies, including cancer vaccines and adoptive T-cell receptor (TCR-T) therapies, which aim to stimulate or provide T cells specifically reactive to these complexes (Source: Immatics N.V.). By targeting these specific peptide-MHC complexes, researchers hope to achieve high tumor specificity and recruit a broad range of immune effectors to the tumor microenvironment. However, challenges such as the downregulation of HLA molecules by the tumor and the risk of off-target toxicity against healthy tissues expressing similar peptides remain significant hurdles in clinical development (Source: Johnson et al., 2020, PMID: 32814062).

Other names

MHC class II-melanoma antigen complexHLA-DR-melanoma peptide complexMelanoma-associated antigen-HLA class II complexpMHCII complex

Recognition and binding of the peptide-MHC complex by antigen-specific T-cell receptors (TCRs) on CD4+ T-lymphocytes, triggering immune activation and tumor cell lysis (Source: Pollack et al., 2017, PMID: 28630100).